Jan de Backer – CEO, Fluidda
Fluidda is the world leader in the field of functional respiratory imaging which combines HRCT scans and computational fluid dynamics technology. CEO Jan de Backer outlines the major developments of…
Address: Turnhoutseweg 30, B-2340 Beerse – Belgium
Tel: +32 (0)14 60 21 11
Web: http://www.janssenpharmaceutica.be/
Our Belgian branches are responsible for a number of the core activities of the Janssen Pharmaceutical Group. Various departments in Belgium are, in fact, worldwide “Centers of Excellence” (CoE’s) in their area of expertise.
The search for medicines that treat unmet medical needs continues to form the main thrust of our research activities. This means that we focus primarily on those disease areas for which no effective treatments are available yet.
Our main therapeutic areas are:
Neurosciences
Infectious diseases
Immunology
Oncology
Cardiovascular conditions
Fluidda is the world leader in the field of functional respiratory imaging which combines HRCT scans and computational fluid dynamics technology. CEO Jan de Backer outlines the major developments of…
Pierre Fabre Benelux General Manager Kristel de Bisschop discusses the challenges and opportunities inherent in taking charge of an important affiliate against the backdrop of a group-wide transformation push and…
Kevin Houdenaert, general manager for Benelux and the Nordics at Italian rare disease, specialty and primary care specialist Recordati, gives an overview of the market access specificities of the markets…
Squirreled away in the lowlands of North West Europe and somewhat dwarfed by the mighty neighbouring pharmaceutical powerhouses of Germany and France, one could easily be forgiven for overlooking Belgium’s…
Belgium is a vitally important country for Johnson & Johnson’s pharmaceutical arm, Janssen, globally. In addition to their R&D centre and a pharma production plant in Beerse, Janssen also has…
Belgian doctor, researcher and professor, Stéphane De Wit has been with the St Pierre University Hospital in Brussels since 1983. Initially planning to specialize in intensive care, his first internship…
Belgium’s healthcare system was ranked fourth in Europe in 2019, outperforming its peers across a number of metrics including a relatively high number of hospital beds per capita (six per…
Carl Laurent, managing director and CEO of Siemens Healthineers BeLux, sits down with PharmaBoardroom to explain Siemens Healthineers’ footprint and impact in Belgium and Luxembourg, the importance of appreciating diagnostics…
Axel De Muyt, general manager & VP of Novo Nordisk Belgium and Luxembourg, recounts his journey through the pharma industry, how he has been able to revive the company’s perspectives…
In late 2019 Novartis hit the headlines in Belgium after it refused to grant access to its one-off gene therapy Zolgensma® for the ultra-rare muscle-wasting disease spinal muscular atrophy (SMA)…
GSK, the world’s largest manufacturer of vaccines, has pursued a different strategy to that of its contemporaries in the effort to develop a safe, effective, and mass-producible COVID-19 vaccine. PharmaBoardroom…
Alexander Alonso, general manager of medtech giant BD’s operations in Belgium, the Netherlands, and Luxembourg outlines the company’s extensive footprint in the region, how it has rapidly mobilised in the…
See our Cookie Privacy Policy Here
